Please assess the completion status of the following clinical trial:

Trial Title: REstart or STop Antithrombotic Randomised Trial in France

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient age ≥18 years.~* Spontaneous intracerebral hemorrhage confirmed by imaging~* Patient had been taken antithrombotic drug(s) for the prevention of vaso-occlusive disease for at least 1 week before ICH onset~* Randomisation more than 24 hours after ICH onset.~* Patient and their doctor are uncertain about whether to start or avoid antiplatelet drugs.~* Brain imaging that first diagnosed the ICH is available. Participant or representative consent.~Exclusion Criteria:~* intracerebral hemorrhage associated with : a vascular malformation (AVM, arterial aneurysm, cavernoma); a secondary hemorrhagic infarction; a cerebral venous thrombosis; a tumor~* Patients with a formal indication of restarting oral anticoagulants despite the ICH (eg mechanical heart valves or pulmonary embolism under 6 months)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Start antiplatelet drug(s) (Type: EXPERIMENTAL): If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
- Avoid antiplatelet drug(s) (Type: NO_INTERVENTION): If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period

Based on this trial design, predict the completion outcome and termination type (if applicable).